COVID-19: We want to help you to continue to stay protected and covered with your insurance plan
COVID-19: Special Financial Assistance Programme
COVID-19: Premium Deferment Programme (PDP)
COVID-19: 30-Day Waiting Period Waived for Medical Plans
COVID-19: Waiver of 90-Day Exclusion for Overseas Medical Treatment Claims Due to Travel Restriction
COVID-19: We want to help you to continue to stay protected and covered with your insurance plan
COVID-19: Special Financial Assistance Programme
COVID-19: Premium Deferment Programme (PDP)
COVID-19: 30-Day Waiting Period Waived for Medical Plans
COVID-19: Waiver of 90-Day Exclusion for Overseas Medical Treatment Claims Due to Travel Restriction
Special Flood Relief Assistance for Our Customers
Digitalised Welcome Call for Manulife Customers
Download your policy contract via eLITE Customer Portal!
Circulation of Suspicious Message (allegedly referring to Manulife)
Announcement on Manulife Insurance Berhad (MIB) Branch Services
Branch Operating Hours Beginning 4 May 2020
New Payment Acceptance guidelines at Branches:
Participating Fund Statement 2019
Guide to Investment-linked Policy Owners on Insurance Coverage
The Sales and Service Tax (SST) will be implemented on Sept 1, 2018
Common Reporting Standard - Brochure & Frequently Asked Questions
Personal Data Protection Notice
FAQ - Removal of Upgraded Room and Board Co-Payment for MedCare Plus 2
FAQ - Removal of Upgraded Room and Board Co-Payment for ManuMedic series
FAQ - Goods and Services Tax (GST)
Refer to the List of Funds available to HSBC FlexiLife and HSBC FlexiLife Gold page for more information
Refer to the Closure of Manulife Asian Small Cap Growth Fund and Manulife Emerging Eastern Europe Fund page for more information
Refer to the Manulife Managed Fund: Enhancement to Fund Mandate page for more information
Refer to the Discontinuance of MASCG and MEEEE page for more information.
Refer to the Medical Repricing page for more information.
Prior to 28 October 2019, the underlying master fund of Manulife Emerging Eastern Europe Fund, namely Manulife Global Fund-Emerging Eastern Europe Fund (MGF-EEEF) charges Annual Performance Fee, which will only be applicable when the Net Asset Value exceeds the Target Net Asset Value for the particular financial year ('Excess'). The Annual Performance Fee is equivalent to 8% of the Excess.
For the benefits of policyowners, this Annual Performance Fee is removed effective 28 October 2019
Refer to the Frequently Asked Question (FAQ) for more information.
With effect from 24 Jan 2019, the List of Covered Events has been extended to include the following critical illnesses:
List of eligible products are as follows:
*Only Occupationally Acquired HIV Infection and Brain Surgery will be included, where the current Elite Credit Shield already covers Terminal Illness.
This extension shall also apply retrospectively to existing policy issued from 1 Jan 2015 onwards. The standard 30 days Waiting Period and Pre-Existing Condition clause shall be applicable.
Premium rates/insurance charges, all other features and benefits, as well as terms and conditions of the eligible products shall remain unchanged.
With effect from 9 Jan 2019, the List of Covered Events has been extended to include the following critical illnesses:
List of eligible products are as follows:
This extension shall also apply retrospectively to existing policy issued from 1 Jan 2015 onwards. The standard 30 days Waiting Period and Pre-Existing Condition clause shall be applicable.
Premium rates/insurance charges, all other features and benefits, as well as terms and conditions of the eligible products shall remain unchanged.
With effect from 18 May 2018, the "Upgraded Room and Board Co Payment" clause will be removed for MedCare Plus 2 attachable to Elite Smart Life, Elite Smart Kids and Elite Prime Life. This removal shall be applied retrospectively to existing MedCare Plus 2 Policy owner.
Insurance charges, all other features and benefits, as well as the Terms and Conditions of MedCare Plus 2 shall remain unchanged. For any question on the removal of Upgraded Room and Board Co-Payment, please contact your authorised bank representative or refer to the Frequently Asked Question (FAQ) for more information.
With effect from 5-January-2018, the ‘Upgraded Room and Board Co-Payment” will be removed for the medical products listed below retrospectively:
Insurance charges, all other features and benefits, as well as the Terms and Conditions of the products listed above shall remain unchanged. For any question on the removal of Upgraded Room and Board Co-Payment, please contact your servicing agent or refer to the Frequently Asked Question (FAQ) for more information.
The Corporate Outsource Services Sdn Bhd (COSSB) hotline number for hospital admissions will be changed to 1300 88 0100 with effect from 31 December 2017.
Effective 15 November 2017, the target fund for Manulife China Value Fund will be changed from Manulife Global Fund-China Value Fund (MGF-CVF) to Manulife Investment-Greater China Fund (MI-GCF)
Refer to the Frequently Asked Question (FAQ) for more information.
Effective 1 December 2018, the Investment Objective of SIP Aggressive Portfolio, SIP Growth Portfolio and SIP Balanced Portfolio will be replaced as follows and such change will not result in changes in the investment objective and strategy of the Fund:
The Underlying Funds (including its fund manager) and asset allocations may be changed as and when the Company deems appropriate, provided it is in line with the Fund's investment objective and strategy.